The Tamil Nadu Government is planning to set up biotechnology enterprise zones to use the bio-resources available with the
state. The Maharashtra government also has been promoting biotech parks and R&D centers. The Karnataka government has formulated
a biotechnology policy for the promotion of the biotechnology industry. It is setting up an Institute of Bioinformatics and
Applied Biotechnology (IBAB) in partnership with ICICI this year. IBAB has been conducting courses and training programs in
bioinformatics and biotechnology. It has also been promoting the incubation of new startups in the biotech industry, and conducting
research and development in the field of bioinformatics and other related areas.
Figure 1. Biopharmaceutical segments percentage sales: 2004–2005
Industry Associations and Institutions
There are several associations, such as the Association of Biotech-led Enterprises (ABLE), the Confederation of Indian Industries
(CII), the Federation of Indian Chambers of Commerce and Industry (FICCI), Biospectrum, and the All India Biotech Association
(AIBA), that actively represent the interests of the biotechnology industry. These associations have been instrumental in
bringing about changes in regulations to strengthen the biopharmaceutical market.
Strength of Local Companies
Overall, the Indian biopharmaceutical industry comprises 350 biopharmaceutical companies, of which 50% are involved in product
development, 20% are involved in clinical development, 15% provide research services, and 5% focus on platform technologies.
Companies such as Biocon, Serum Institute, Bharat Biotech, Shantha Biotech, and Panaceam, (Table 1), are some of the key players
in the Indian biopharmaceutical sector.
Table 1. Indian biopharmaceutical companies and their performance
The Indian biopharmaceutical sector registered record sales of $1.45 billion from 2006–2007, showing 26.87% growth over the
previous fiscal year. Biotechnology investment, both in R&D and infrastructure, surpassed $51.04 million in 2006–2007, a 38%
increase over the previous fiscal year. According to the 2007 Biospectrum-ABLE Survey, the biopharmaceutical sector is export-driven,
and about 70% of India's biopharmaceutical exports are small-molecule active pharmaceutical ingredients. The Indian market
is witnessing a considerable growth in recombinant products. In 2003–2004, DBT estimated the domestic market for recombinant
therapeutics at about $94.19 million. This sector represents about 3.2% of the total pharmaceutical market in India and 1.6%
of the world market of recombinant therapeutics. There were 50 branded biotech drugs developed in India in 2006–2007, and
this figure could increase to 100 by 2010.
In particular, India is emerging as major player in the vaccines business. In 2005–2006, vaccine sales accounted for more
than 38% of India's total biopharmaceutical sector of $1,094.88 billion.6 In 2005–2006, India's vaccines business was estimated at $400 million (Figure 1). Indian companies like Serum institute,
Shantha Biotech, Bharat Biotech, Indian immunological, Biocon, have established capacities for manufacturing recombinant therapeutics